BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12640448)

  • 1. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates.
    Schmidt M; Carbonaro DA; Speckmann C; Wissler M; Bohnsack J; Elder M; Aronow BJ; Nolta JA; Kohn DB; von Kalle C
    Nat Med; 2003 Apr; 9(4):463-8. PubMed ID: 12640448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
    Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
    Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
    Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
    Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
    Ramsey WJ; Mullen CA; Blaese RM
    Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential.
    Ficara F; Superchi DB; Hernández RJ; Mocchetti C; Carballido-Perrig N; Andolfi G; Deola S; Colombo A; Bordignon C; Carballido JM; Roncarolo MG; Aiuti A
    Mol Ther; 2004 Dec; 10(6):1096-108. PubMed ID: 15564141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene therapy for adenosine deaminase deficiency].
    Sakiyama Y
    Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-transferred oligoclonal T cells predominantly persist in peripheral blood from an adenosine deaminase-deficient patient during gene therapy.
    Misaki Y; Ezaki I; Ariga T; Kawamura N; Sakiyama Y; Yamamoto K
    Mol Ther; 2001 Jan; 3(1):24-7. PubMed ID: 11162307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic progenitor cells.
    Plavec I; Voytovich A; Moss K; Webster D; Hanley MB; Escaich S; Ho KE; Böhnlein E; DiGiusto DL
    Gene Ther; 1996 Aug; 3(8):717-24. PubMed ID: 8854097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.
    Kohn DB; Weinberg KI; Nolta JA; Heiss LN; Lenarsky C; Crooks GM; Hanley ME; Annett G; Brooks JS; el-Khoureiy A
    Nat Med; 1995 Oct; 1(10):1017-23. PubMed ID: 7489356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroviral vector for gene therapy of X-linked severe combined immunodeficiency syndrome.
    Qazilbash MH; Walsh CE; Russell SM; Noguchi M; Mann MM; Leonard WJ; Liu JM
    J Hematother; 1995 Apr; 4(2):91-8. PubMed ID: 7633846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
    Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
    N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.
    Carbonaro DA; Zhang L; Jin X; Montiel-Equihua C; Geiger S; Carmo M; Cooper A; Fairbanks L; Kaufman ML; Sebire NJ; Hollis RP; Blundell MP; Senadheera S; Fu PY; Sahaghian A; Chan RY; Wang X; Cornetta K; Thrasher AJ; Kohn DB; Gaspar HB
    Mol Ther; 2014 Mar; 22(3):607-622. PubMed ID: 24256635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ADA gene expression and transduction efficiency in ADA/SCID patients undergoing gene therapy.
    Carlucci F; Tabucchi A; Aiuti A; Rosi F; Floccari F; Pagani R; Marinello E
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1245-8. PubMed ID: 15571238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
    Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
    Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
    Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
    Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
    [No Abstract]   [Full Text] [Related]  

  • 20. Transduction of CD34-enriched human peripheral and umbilical cord blood progenitors using a retroviral vector with the Fanconi anemia group C gene.
    Walsh CE; Mann MM; Emmons RV; Wang S; Liu JM
    J Investig Med; 1995 Aug; 43(4):379-85. PubMed ID: 7552587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.